Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by AngioDynamics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: AngioDynamics’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 3:42 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001628280-26-048138
| Line item | Year ended May 31, 2026 | Year ended May 31, 2025 | Year ended May 31, 2024 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net loss | $(36,742) | $(33,993) | $(184,349) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 22,955 | 25,800 | 27,712 |
| Non-cash lease expense | 1,555 | 1,958 | 1,931 |
| Non-cash interest expense | 290 | — | — |
| Goodwill impairment | — | — | 159,476 |
| Stock based compensation | 13,960 | 9,772 | 10,529 |
Item 15. Exhibits, Financial Statement Schedules.
FAQ
- What is AngioDynamics's D&A?
- AngioDynamics (ANGO) reported D&A of $5.6M in Q1 2026.
- How has AngioDynamics's D&A changed year-over-year?
- AngioDynamics's D&A decreased by 4.0% year-over-year, from $5.83M to $5.6M.
- What is the long-term trend for AngioDynamics's D&A?
- Over 4 years (2022 to 2026), AngioDynamics's D&A has grown at a -6.0% compound annual growth rate (CAGR), from $29.35M to $22.96M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about AngioDynamics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude